Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

Abstract:

BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic outcomes. We aimed to systematically review evidence regarding factors associated with LRR and to propose a framework for adjuvant radiotherapy (RT) in patients with MIBC. METHODS:We performed this systematic review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. We searched the PubMed database for articles related to MIBC and associated treatments, published between January 1980 and June 2015. Articles identified by searching references from candidate articles were also included. We retrieved 1383 publications from PubMed and 34 from other sources. After an initial screening, a review of titles and abstracts, and a final comprehensive full text analysis of papers assessed for eligibility, a final consensus on 32 studies was obtained. RESULTS:LRR is associated with specific patient-, tumor-, center- or treatment-related variables. LRR varies widely, occurring in as many as 43% of the cases and is strongly related to survival outcomes. While perioperative treatment does not impact on LRR, pathological factors such as pT, pN, positive margins status, extent of PLND, number of lymph nodes removed and/or invaded are correlated with LRR. Patients with pT3-T4a and/or positive lymph-nodes and/or limited pelvic lymph-node dissection and/or positive surgical margins have been distributed in LRR risk groups with accuracy. CONCLUSIONS:LRR patterns are well-known and for selected patients, adjuvant treatments could target this event. Intrinsic tumor subtype may guide future criteria to define a personalized treatment strategy. Prospective trials evaluating safety and efficacy of adjuvant RT are ongoing in several countries.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

doi

10.1016/j.ctrv.2018.07.011

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

88-97

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(18)30130-0

journal_volume

70

pub_type

杂志文章,评审
  • The emerging role of MET/HGF inhibitors in oncology.

    abstract::The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2013.02.001

    authors: Scagliotti GV,Novello S,von Pawel J

    更新日期:2013-11-01 00:00:00

  • Neck lymph node metastases from unknown primary.

    abstract::Metastatic cervical carcinoma from unknown primary is a metastatic disease in the lymph nodes of the neck without any evidence of a primary tumour after appropriate investigation. The condition is rare and definite evidence is lacking for both diagnosis and treatment. In this review of the literature, we tried to draw...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.11.014

    authors: Arosio AD,Pignataro L,Gaini RM,Garavello W

    更新日期:2017-02-01 00:00:00

  • Is there a role for a specialized follow-up clinic for survivors of pediatric cancer?

    abstract::Due to advances in chemotherapy and supportive care, greater than 70% of patients with childhood cancer will survive 5 years. However, there are long-term physiological and psychological sequelae of these treatments that may not manifest until pediatric survivors are into adulthood. Various studies done in the long-te...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.014

    authors: Prasad PK,Bowles T,Friedman DL

    更新日期:2010-06-01 00:00:00

  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

    abstract::The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key chal...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.02.006

    authors: Lim SM,Syn NL,Cho BC,Soo RA

    更新日期:2018-04-01 00:00:00

  • Developments in the systemic treatment of metastatic cervical cancer.

    abstract::Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally advanced disease, or as monotherapy for recurrent/metast...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.05.009

    authors: Mountzios G,Soultati A,Pectasides D,Pectasides E,Dimopoulos MA,Papadimitriou CA

    更新日期:2013-08-01 00:00:00

  • Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

    abstract::Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.08.012

    authors: Custodio A,Puente J,Sastre J,Díaz-Rubio E

    更新日期:2009-12-01 00:00:00

  • A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

    abstract:BACKGROUND:We performed a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy (NHT) in localised and locally advanced prostate cancer to assess the effectiveness of this therapy. METHODS:We searched MEDLINE, The Cochrane Library, Science Citation Index, LILACS and SIGLE for randomi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2008.08.002

    authors: Shelley MD,Kumar S,Wilt T,Staffurth J,Coles B,Mason MD

    更新日期:2009-02-01 00:00:00

  • The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures.

    abstract::With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00038-5

    authors: Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

    更新日期:2002-08-01 00:00:00

  • The role of PET/CT in the modern treatment of Hodgkin lymphoma.

    abstract::Classical Hodgkin Lymphoma is distinguished from other lymphomas by its peculiar biology and heterogeneous chemosensitivity. Most of the patients respond to the standard first-line treatment and are cured, however, in selected cases, the disease relapses or remains primarily refractory. Among predictive/prognostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2019.06.002

    authors: Zaucha JM,Chauvie S,Zaucha R,Biggii A,Gallamini A

    更新日期:2019-07-01 00:00:00

  • Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

    abstract::Biliary tract cancer is a quite rare disease; despite recent significant advances in imaging modalities, most of the patients have advanced disease at presentation thus making radical surgery not feasible. Many different chemotherapeutic regimens have been investigated in small uncontrolled studies, with generally dis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.03.003

    authors: Berardi R,Scartozzi M,Freddari F,Squadroni M,Santinelli A,Bearzi I,Fabris G,Cascinu S

    更新日期:2006-08-01 00:00:00

  • Targeting uPA/uPAR in prostate cancer.

    abstract::Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP met...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.06.003

    authors: Li Y,Cozzi PJ

    更新日期:2007-10-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2009.02.005

    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00

  • The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies.

    abstract::Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(02)00107-x

    authors: Sakorafas GH

    更新日期:2003-04-01 00:00:00

  • Cancer surgery: the last 25 years.

    abstract::Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 历史文章,杂志文章,评审

    doi:10.1053/ctrv.1999.0147

    authors: Bremers AJ,Rutgers EJ,van de Velde CJ

    更新日期:1999-12-01 00:00:00

  • Phase I study and pharmacokinetics of intraperitoneal carboplatin.

    abstract::In the early stages of this phase I study the tolerance of carboplatin intraperitoneally was good. Pharmacokinetic profiles suggest a possible therapeutic advantage for giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. The extent of penetration of carboplatin through tum...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(85)90016-7

    authors: McVie JG,ten Bokkel Huinink W,Dubbelman R,Franklin H,van der Vijgh W,Klein I

    更新日期:1985-09-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Update on capecitabine alone and in combination regimens in colorectal cancer patients.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profil...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/S0305-7372(10)70020-7

    authors: Silvestris N,Maiello E,De Vita F,Cinieri S,Santini D,Russo A,Tommasi S,Azzariti A,Numico G,Pisconti S,Petriella D,Lorusso V,Millaku A,Colucci G

    更新日期:2010-11-01 00:00:00

  • PARP inhibitors in ovarian cancer.

    abstract::Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways,...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.12.002

    authors: Franzese E,Centonze S,Diana A,Carlino F,Guerrera LP,Di Napoli M,De Vita F,Pignata S,Ciardiello F,Orditura M

    更新日期:2019-02-01 00:00:00

  • Cancer stem cells niche: a target for novel cancer therapeutics.

    abstract::Nowadays, cancer has been a frequent disease, and the first or second most common cause of death worldwide. Despite a better understanding of the biology of cancer cells, the therapy of most cancers has not significantly changed for the past four decades. It is because conventional chemotherapies and/or radiation ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.10.004

    authors: Yi SY,Hao YB,Nan KJ,Fan TL

    更新日期:2013-05-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.001

    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • The role of bone markers in metastatic bone disease.

    abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(06)80001-0

    authors: Coleman RE

    更新日期:2006-01-01 00:00:00

  • A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer.

    abstract::Diffusion-weighted magnetic resonance imaging (DW-MRI) is used extensively to improve tumour detection and localization because it offers excellent soft tissue contrast between malignant and non-malignant tissues. It also provides a quantitative biomarker; the apparent diffusion coefficient (ADC) can be derived from D...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.03.010

    authors: Bollineni VR,Kramer G,Liu Y,Melidis C,deSouza NM

    更新日期:2015-06-01 00:00:00

  • Adjuvant immunotherapy for non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. Over a million people will die of lung cancer worldwide this year alone. When possible, surgery to remove the tumor is the best t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.11.008

    authors: Tucker ZC,Laguna BA,Moon E,Singhal S

    更新日期:2012-10-01 00:00:00

  • The expanding role of immunotherapy.

    abstract::The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landsc...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.01.008

    authors: Martin-Liberal J,Ochoa de Olza M,Hierro C,Gros A,Rodon J,Tabernero J

    更新日期:2017-03-01 00:00:00

  • Gender and survival in malignant tumours.

    abstract:BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids ca...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.2001.0220

    authors: Molife R,Lorigan P,MacNeil S

    更新日期:2001-08-01 00:00:00

  • Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.

    abstract::In the last ten years, the development of several novel targeted drugs and the refinement of state of the art technologies such as the genomics and proteomics and their introduction to clinical practice have revolutionized the management of patients affected by cancer. However, everyday practice points out several cli...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2007.10.001

    authors: Pantaleo MA,Nannini M,Maleddu A,Fanti S,Ambrosini V,Nanni C,Boschi S,Biasco G

    更新日期:2008-04-01 00:00:00

  • Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature.

    abstract:BACKGROUND:Different modalities of treatment in early laryngeal cancer lead to equivalent oncological outcomes. Hence this systematic review was undertaken to synthesise the key oncological outcomes following primary open partial laryngectomy for laryngeal cancer. METHODS:A systematic review of the English literature ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2011.05.010

    authors: Thomas L,Drinnan M,Natesh B,Mehanna H,Jones T,Paleri V

    更新日期:2012-05-01 00:00:00

  • Megestrol acetate: clinical experience.

    abstract::The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity pro...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(89)90004-2

    authors: Schacter L,Rozencweig M,Canetta R,Kelley S,Nicaise C,Smaldone L

    更新日期:1989-03-01 00:00:00

  • Circulating tumor cells in colorectal cancer patients.

    abstract::The availability of sensitive methods has allowed the detailed study of circulating tumor cells only recently. Evolving evidence support the prognostic and predictive role of these cells in patients affected by several solid tumors, including colorectal cancer. Ongoing studies are aimed at confirming that the molecula...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.12.007

    authors: Torino F,Bonmassar E,Bonmassar L,De Vecchis L,Barnabei A,Zuppi C,Capoluongo E,Aquino A

    更新日期:2013-11-01 00:00:00

  • Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.

    abstract::Management of early stages non-small cell lung carcinoma has traditionally been surgery with radiation selected for medically inoperable patients. Recent emergence of stereotactic body radiation therapy allows for delivery of high radiation dose to the tumor while sparing normal lungs. This reviews compares loco-regio...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2008.06.001

    authors: Nguyen NP,Garland L,Welsh J,Hamilton R,Cohen D,Vinh-Hung V

    更新日期:2008-12-01 00:00:00